Image: Bethany Beck/ Unsplash When Hillary Tolle Carter's 13-year-old son casually told her, "You don't need to manage my ...

Discover What’s Streaming On: We know that there are still some people who are catching up on the fourth season of From, so we’ll keep this article spoiler-free. That said, if you’ve already watched ...

If you’re looking to watch the newest episode of MGM+’s fan favorite From (Season 4, Episode 8: “Heavy Is the Head”), you’ll be happy to know that it’s now streaming on MGM+ and Philo. Not only that, ...

Kashiv BioSciences Announces Validation and Acceptance of Market Authorization Application by Health Canada for ADL-018, a Proposed Biosimilar to XOLAIR®(omalizumab) Kashiv BioSciences, LLC (“Kashiv”) ...

Clinical data from a phase 3 trial show Ponlimsi has comparable safety and efficacy to Prolia in women with postmenopausal osteoporosis. The Food and Drug Administration (FDA) has approved Ponlimsi ™ ...

DBV Technologies (DBVT) trades at a ~$1B market cap, but Viaskin faces a shrinking peanut allergy market and formidable competition, warranting caution. Viaskin’s addressable market is materially ...

The Food and Drug Administration has approved Teva's Prolia biosimilar, and the agency is reviewing Teva's Xolair biosimilar application. “The FDA approval of Ponlimsi is a significant milestone that ...

Please provide your email address to receive an email when new articles are posted on . Individuals received 8-week omalizumab followed by either 24-week dupilumab or placebo. The groups significantly ...

Novartis has penned a $2 billion deal for a biotech whose next-gen anti-immunoglobulin E (IgE) program could offer a worthy successor to Xolair. Excellergy has been snapped up by the Swiss pharma only ...

Individuals with one to three allergenic foods are able to introduce and continue eating allergenic foods at 12 months after multifood oral immunotherapy (mOIT) or omalizumab, according to a study ...